Publications

Publications

Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.

J Mol Med (Berl). 2016 Dec;94(12):1411-1422

Wang T, Abou-Ouf H, Hegazy SA, Alshalalfa M, Stoletov K, Lewis J, Donnelly B, Bismar TA

Abstract

Ankyrin G (ANK3) is a member of the Ankyrin family, which functions to provide cellular stability by anchoring the cytoskeleton to the plasma membrane. Deregulation of ANK3 expression has been observed in multiple human cancers but its mechanism remains unknown. ANK3 expression in relation to disease progression and patients’ outcome was investigated in two cohorts of prostate cancer (PCA). Mechanistic studies were carried out in vitro and in vivo using several PCA cell lines and the avian embryo model. Silencing ANK3 resulted in significant reduction of cell proliferation through an AR-independent mechanism. Decreased ANK3 expression delayed S phase to G2/M cell cycle transition and reduced the expression of cyclins A and B. However, cells with knocked-down ANK3 exhibited significant increase in cell invasion through an AR-dependent mechanism. Furthermore, we found that ANK3 is a regulator of AR protein stability. ANK3 knockdown also promoted cancer cell invasion and extravasations in vivo using the avian embryo model (p < 0.01). In human samples, ANK3 expression was dramatically upregulated in high grade intraepithelial neoplasia (HGPIN) and localized PCA (p < 0.0001). However, it was downregulated castration resistant stage (p < 0.0001) and showed inverse relation to Gleason score (p < 0.0001). In addition, increased expression of ANK3 in cancer tissues was correlated with better cancer-specific survival of PCA patients (p = 0.012).

KEY MESSAGE:

Silencing ANK3 results in significant reduction of cell proliferation through an AR-independent mechanism. ANK3 knockdown results in significant increase in cell invasion through an AR-dependent mechanism. ANK3 is a regulator of AR protein stability. ANK3 knockdown also promotes cancer cell invasion and extravasation in vivo using the avian embryo model.

PubMed

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Dr. John Lewis recognized for a breakthrough innovation with commercial application: ClarityDX Prostate

Alberta’s life sciences industry association; BioAlberta, hosted its 2018 awards gala in Calgary, September 24. BioAlberta honoured Dr. John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research and an Associate Professor at the University of Alberta, with its Scientific Achievement and Innovation Award.

The Scientific Achievement and Innovation award recognizes an individual or a team responsible for a breakthrough innovation with commercial application. John Lewis and his research team based with his spin-off company Nanostics Inc. developed ClarityDX Prostate, a blood test designed to accurately diagnose aggressive prostate cancer. ClarityDX Prostate will give clinicians and physicians another tool to help them and their patients decide to perform a biopsy, or not. When the test becomes commercially available it is expected to reduce the number of prostate biopsies by 50%.

BioAlberta also gave out The Company of the Year award to Circle Cardiovascular Imaging Inc. for significant achievement within the marketplace and Alberta’s business community. It has developed technology to produce an innovative post-processing cardiovascular imaging solution to improve patient outcomes that provides fast, accurate and reproducible images to assist physicians in earlier diagnosis and treatment.

Mel Wong, President and CEO of BioAlberta presented the awards with these comments, “We commend Circle Cardiovascular Imaging and Dr. John Lewis for their exceptional achievements in life sciences, Alberta’s life sciences industry is maturing and these award winners exemplify Alberta’s capacity for global impact.”

More than 200 representatives from industry, the investment community, government and innovation support organizations attended the awards gala that was held in partnership with TEC Edmonton, and with generous event sponsors. Read more in this Financial Post article.

Congratulations to John Lewis on receiving BioAlberta’s Scientific Achievement and Innovation Award!

- Perrin Beatty